Cox-2 vs.Other NSAID Use in Children with JRA Data from a cohort study, Beth Gottlieb, MD, Asst. Professor of Pediatrics, Schneider Children’s Hospital, New Hyde Park, NY Kathleen A. Haines, MD Section Chief, Pediatric Immunology Section of Pediatric Rheumatology and Immunology Hackensack University Medical Center Hackensack, NJ

Long Term Outcome Study of Children with JRA Prospective observational, multi-center study of children with JRA enrolled at onset Purpose was to collect data on outcomes of the various treatments used by pediatric rheumatologists Non-interventional study Support was obtained from the Arthritis Foundation

Long Term Outcome Study of Children with JRA Rheumatologists participated in an IRB-approved study –Enrolled patients within 6 weeks of diagnosis –Treatment was initiated according to the treating MD’s usual practice –At enrollment and on an annual basis, data including physical exam, treatment given, side effects of treatment and outcome measures were recorded and sent to the coordinating center Two cohorts were available for study –Cohort 1 -- diagnosed between Data collected by Suzanne Bowyer, MD, James Whitcomb Riley Children’s Hospital, Indianapolis, IN –Cohort 2 – diagnosed from 2001 to present Data collected by Beth Gottlieb, MD, Schneider Children’s Hospital, New Hyde Park, NY

Long Term Outcome Study of Children with JRA 1115 patients are in the data base (from both cohorts) –60% Pauciarticular JRA –32% Polyarticular JRA –8% Systemic Onset JRA –35 patients were not classified 588 on NSAIDS had evaluable data 58 took a COX-2 inhibitor (rofecoxib or celecoxib) No serious adverse events were reported

Long Term Outcome Study of Children with JRA COX-2 N=58 Other NSAID N=530 Cardiovascular00 Abdominal pain54 Skin changes04 CNS ( mood,hyperactivity) 2? Other04